{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T08:02:16Z","timestamp":1781596936747,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Oslo University Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Genital erosive lichen planus (GELP) is a genital subtype of lichen planus, a chronic autoimmune inflammatory disease of unknown aetiology. In women, GELP is characterised by painful vulvo-vaginal mucosal erosions and scarring, often resulting in poor sexual health and reduced quality of life. Treatment options are limited and often with little effect. Apremilast, a phosphodiesterase 4-inhibitor, has been shown to have a positive effect on psoriasis and other inflammatory skin diseases. We aim to investigate the effect and safety of peroral apremilast in women with GELP in a randomised placebo-controlled double-blinded clinical trial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We will recruit 42 adult women with characteristic clinical and\/or histological features of moderate-to-severe GELP from a specialised vulva clinic in Oslo, Norway. The patients will be randomised 1:1 to either apremilast 30\u2009mg BID (with an initial dose titration on days 1\u20136) or a placebo for 24\u2009weeks. The concomitant use of topical corticosteroids will be allowed. The primary end point will be the mean GELP score, a clinical scoring system, at week 24 in the apremilast-treated patients versus the placebo-treated patients. The secondary end points will include the mean GELP score improvement from weeks 0 to 24, patient-reported use of topical steroids, the pain score on a visual analogue scale and the number of patients with GELP score improvements at weeks 16 and 24. The Physician Global Assessment , Patient Global Assessment and selected quality of life and sexual function assessments will be recorded at weeks 0, 16 and 24. The exploratory endpoints include description of immunohistochemical changes before and after apremilast therapy, assessed in vulvar or vaginal biopsies at weeks 0 and 24. Regular follow-ups for possible adverse events will be conducted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The study design is based on experience from studies on apremilast in other inflammatory skin diseases using equivalent apremilast doses for approved indications. The trial may provide evidence for the use of apremilast in women with this burdensome genital dermatosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03656666?term=ap-gelp&amp;draw=2&amp;rank=1\">NCT0365666<\/jats:ext-link>. Registered on 4 September 2018.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-021-05428-w","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T09:02:59Z","timestamp":1626771779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Apremilast for genital erosive lichen planus in women (the AP-GELP Study): study protocol for a randomised placebo-controlled clinical trial"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6945-775X","authenticated-orcid":false,"given":"Kristin Helene","family":"Skullerud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petter","family":"Gjersvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Are Hugo","family":"Pripp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Qvigstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Lise Ording","family":"Helgesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"issue":"2","key":"5428_CR1","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ejogrb.2013.09.038","volume":"171","author":"FM Lewis","year":"2013","unstructured":"Lewis FM, Bogliatto F. Erosive vulval lichen planus--a diagnosis not to be missed: a clinical review. Eur J Obstet Gynecol Reprod Biol. 2013;171(2):214\u20139. https:\/\/doi.org\/10.1016\/j.ejogrb.2013.09.038.","journal-title":"Eur J Obstet Gynecol Reprod Biol."},{"issue":"4","key":"5428_CR2","doi-asserted-by":"publisher","first-page":"180","DOI":"10.12788\/j.sder.2015.0178","volume":"34","author":"K Zendell","year":"2015","unstructured":"Zendell K. Genital lichen planus: update on diagnosis and treatment. Semin Cutan Med Surg. 2015;34(4):180\u20136.","journal-title":"Semin Cutan Med Surg."},{"issue":"3","key":"5428_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ogc.2017.04.004","volume":"44","author":"M Mauskar","year":"2017","unstructured":"Mauskar M. Erosive lichen planus. Obst Gynecol Clin North Am. 2017;44(3):407\u20139. https:\/\/doi.org\/10.1016\/j.ogc.2017.04.004.","journal-title":"Obst Gynecol Clin North Am."},{"issue":"7","key":"5428_CR4","doi-asserted-by":"publisher","first-page":"966","DOI":"10.3109\/00016341003681231","volume":"89","author":"AL Helgesen","year":"2010","unstructured":"Helgesen AL, Gjersvik P, Jebsen P, Kirschner R, Tanbo T. Vaginal involvement in genital erosive lichen planus. Acta Obstet Gynecol Scand. 2010;89(7):966\u201370. https:\/\/doi.org\/10.3109\/00016341003681231.","journal-title":"Acta Obstet Gynecol Scand."},{"issue":"2","key":"5428_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/bjd.12334","volume":"169","author":"RC Simpson","year":"2013","unstructured":"Simpson RC, Thomas KS, Leighton P, Murphy R. Diagnostic criteria for erosive lichen planus affecting the vulva: an international electronic-Delphi consensus exercise. Br J Dermatol. 2013;169(2):337\u201343. https:\/\/doi.org\/10.1111\/bjd.12334.","journal-title":"Br J Dermatol."},{"issue":"5","key":"5428_CR6","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/j.1365-2230.2005.01866.x","volume":"30","author":"SM Cooper","year":"2005","unstructured":"Cooper SM, Dean D, Allen J, Kirtschig G, Wojnarowska F. Erosive lichen planus of the vulva: weak circulating basement membrane zone antibodies are present. Clin Exp Dermatol. 2005;30(5):551\u20136. https:\/\/doi.org\/10.1111\/j.1365-2230.2005.01866.x.","journal-title":"Clin Exp Dermatol."},{"issue":"6","key":"5428_CR7","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/j.1468-3083.2006.01559.x","volume":"20","author":"EN Lundqvist","year":"2006","unstructured":"Lundqvist EN, Wahlin YB, Bergdahl M, Bergdahl J. Psychological health in patients with genital and oral erosive lichen planus. J Eur Acad Dermatol Venereol. 2006;20(6):661\u20136. https:\/\/doi.org\/10.1111\/j.1468-3083.2006.01559.x.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"2","key":"5428_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/LGT.0000000000000282","volume":"21","author":"H Cheng","year":"2017","unstructured":"Cheng H, Oakley A, Conaglen JV, Conaglen HM. Quality of life and sexual distress in women with erosive vulvovaginal lichen planus. J Low Genit Tract Dis. 2017;21(2):145\u20139. https:\/\/doi.org\/10.1097\/LGT.0000000000000282.","journal-title":"J Low Genit Tract Dis."},{"issue":"1","key":"5428_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1396-0296.2004.04005.x","volume":"17","author":"M Moyal-Barracco","year":"2004","unstructured":"Moyal-Barracco M, Edwards L. Diagnosis and therapy of anogenital lichen planus. Dermatol Ther. 2004;17(1):38\u201346. https:\/\/doi.org\/10.1111\/j.1396-0296.2004.04005.x.","journal-title":"Dermatol Ther."},{"issue":"3","key":"5428_CR10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1586\/edm.12.20","volume":"7","author":"JK Ho","year":"2012","unstructured":"Ho JK, Hantash BM. Systematic review of current systemic treatment options for erosive lichen planus. Exp Rev Dermatol. 2012;7(3):269\u201382. https:\/\/doi.org\/10.1586\/edm.12.20.","journal-title":"Exp Rev Dermatol."},{"issue":"3","key":"5428_CR11","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1046\/j.1365-2133.2002.488713.x","volume":"147","author":"G Kirtschig","year":"2002","unstructured":"Kirtschig G, van der Meulen AJ, Ion Lipan JW, Stoof TJ. Successful treatment of erosive vulvovaginal lichen planus with topical tacrolimus. Br J Dermatol. 2002;147(3):625\u20136. https:\/\/doi.org\/10.1046\/j.1365-2133.2002.488713.x.","journal-title":"Br J Dermatol."},{"issue":"3","key":"5428_CR12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/1346-8138.12763","volume":"42","author":"K Deen","year":"2015","unstructured":"Deen K, McMeniman E. Mycophenolate mofetil in erosive genital lichen planus: a case and review of the literature. J Dermatol. 2015;42(3):311\u20134. https:\/\/doi.org\/10.1111\/1346-8138.12763.","journal-title":"J Dermatol"},{"issue":"6","key":"5428_CR13","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/ced.12858","volume":"41","author":"L Yeo","year":"2016","unstructured":"Yeo L, Ormerod AD. Oral tacrolimus: a treatment option for recalcitrant erosive lichen planus. Clin Exp Dermatol. 2016;41(6):684\u20135. https:\/\/doi.org\/10.1111\/ced.12858.","journal-title":"Clin Exp Dermatol"},{"key":"5428_CR14","volume":"2","author":"S Cheng","year":"2012","unstructured":"Cheng S, Kirtschig G, Cooper S, Thornhill M, Leonardi-Bee J, Murphy R. Interventions for erosive lichen planus affecting mucosal sites. Cochrane Database Syst Rev. 2012;2:CD008092.","journal-title":"Cochrane Database Syst Rev."},{"issue":"5","key":"5428_CR15","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1111\/bjd.14033","volume":"173","author":"AL Helgesen","year":"2015","unstructured":"Helgesen AL, Warloe T, Pripp AH, Kirschner R, Peng Q, Tanbo T, et al. Vulvovaginal photodynamic therapy vs. topical corticosteroids in genital erosive lichen planus: a randomized controlled trial. Br J Dermatol. 2015;173(5):1156\u201362. https:\/\/doi.org\/10.1111\/bjd.14033.","journal-title":"Br J Dermatol."},{"issue":"1","key":"5428_CR16","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/1741-7015-11-96","volume":"11","author":"N Kumar","year":"2013","unstructured":"Kumar N, Goldminz AM, Kim N, Gottlieb AB. Phosphodiesterase 4-targeted treatments for autoimmune diseases. BMC Med. 2013;11(1):96. https:\/\/doi.org\/10.1186\/1741-7015-11-96.","journal-title":"BMC Med."},{"issue":"1","key":"5428_CR17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s13075-015-0771-6","volume":"17","author":"M Perez-Aso","year":"2015","unstructured":"Perez-Aso M, Montesinos MC, Mediero A, Wilder T, Schafer PH, Cronstein B. Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors. Arthritis Res Ther. 2015;17(1):249. https:\/\/doi.org\/10.1186\/s13075-015-0771-6.","journal-title":"Arthritis Res Ther."},{"issue":"7","key":"5428_CR18","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.cellsig.2016.01.007","volume":"28","author":"PH Schafer","year":"2016","unstructured":"Schafer PH, Truzzi F, Parton A, Wu L, Kosek J, Zhang L-H, et al. Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4\/CD271 complex. Cell Signal. 2016;28(7):753\u201363. https:\/\/doi.org\/10.1016\/j.cellsig.2016.01.007.","journal-title":"Cell Signal."},{"issue":"1","key":"5428_CR19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1477-7525-11-82","volume":"11","author":"V Strand","year":"2013","unstructured":"Strand V, Fiorentino D, Hu C, Day RM, Stevens RM, Papp KA. Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study. Health Qual Life Outcomes. 2013;11(1):82. https:\/\/doi.org\/10.1186\/1477-7525-11-82.","journal-title":"Health Qual Life Outcomes."},{"issue":"1","key":"5428_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","volume":"73","author":"K Papp","year":"2015","unstructured":"Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37\u201349. https:\/\/doi.org\/10.1016\/j.jaad.2015.03.049.","journal-title":"J Am Acad Dermatol."},{"issue":"6","key":"5428_CR21","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/bjd.14164","volume":"173","author":"C Paul","year":"2015","unstructured":"Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52\u2009weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387\u201399. https:\/\/doi.org\/10.1111\/bjd.14164.","journal-title":"Br J Dermatol."},{"issue":"2","key":"5428_CR22","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jaad.2017.01.052","volume":"77","author":"J Crowley","year":"2017","unstructured":"Crowley J, Thaci D, Joly P, Peris K, Papp KA, Goncalves J, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for >\/=156\u2009weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017;77(2):310\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2017.01.052.","journal-title":"J Am Acad Dermatol."},{"issue":"4","key":"5428_CR23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40265-017-0709-1","volume":"77","author":"GM Keating","year":"2017","unstructured":"Keating GM. Apremilast: a review in psoriasis and psoriatic arthritis. Drugs. 2017;77(4):459\u201372. https:\/\/doi.org\/10.1007\/s40265-017-0709-1.","journal-title":"Drugs."},{"issue":"8","key":"5428_CR24","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1001\/archdermatol.2012.812","volume":"148","author":"A Samrao","year":"2012","unstructured":"Samrao A, Berry TM, Goreshi R, Simpson EL. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol. 2012;148(8):890\u20137. https:\/\/doi.org\/10.1001\/archdermatol.2012.812.","journal-title":"Arch Dermatol."},{"issue":"2","key":"5428_CR25","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/09546634.2019.1589641","volume":"31","author":"NJ Maloney","year":"2020","unstructured":"Maloney NJ, Zhao J, Tegtmeyer K, Lee EY, Cheng K. Off-label studies on apremilast in dermatology: a review. J Dermatol Treat. 2020;31(2):131\u201340. https:\/\/doi.org\/10.1080\/09546634.2019.1589641.","journal-title":"J Dermatol Treat"},{"issue":"16","key":"5428_CR26","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","volume":"372","author":"G Hatemi","year":"2015","unstructured":"Hatemi G, Melikoglu M, Tunc R, Korkmaz C, Ozturk BT, Mat C, et al. Apremilast for Beh\u00e7et\u2019s syndrome--a phase 2, placebo-controlled study. N Engl J Med. 2015;372(16):1510\u20138. https:\/\/doi.org\/10.1056\/NEJMoa1408684.","journal-title":"N Engl J Med."},{"issue":"20","key":"5428_CR27","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","volume":"381","author":"G Hatemi","year":"2019","unstructured":"Hatemi G, Mahr A, Ishigatsubo Y, Song Y, Takeno M, Kim D, et al. Trial of apremilast for oral ulcers in Beh\u00e7et\u2019s syndrome. N Engl J Med. 2019;381(20):1918\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1816594.","journal-title":"N Engl J Med."},{"issue":"20","key":"5428_CR28","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1056\/NEJMc1901987","volume":"381","author":"AGA Kolios","year":"2019","unstructured":"Kolios AGA, Yawalkar N, Feusi A, K\u00fcndig T, Boyman O, Nilsson J. Apremilast in treatment-refractory recurrent aphthous stomatitis. N Engl J Med. 2019;381(20):1975\u20137. https:\/\/doi.org\/10.1056\/NEJMc1901987.","journal-title":"N Engl J Med."},{"issue":"2","key":"5428_CR29","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jaad.2012.07.014","volume":"68","author":"J Paul","year":"2013","unstructured":"Paul J, Foss CE, Hirano SA, Cunningham TD, Pariser DM. An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: a case series. J Am Acad Dermatol. 2013;68(2):255\u201361. https:\/\/doi.org\/10.1016\/j.jaad.2012.07.014.","journal-title":"J Am Acad Dermatol."},{"issue":"8","key":"5428_CR30","first-page":"1026","volume":"15","author":"M Bettencourt","year":"2016","unstructured":"Bettencourt M. Oral lichen planus treated with apremilast. J Drugs Dermatol. 2016;15(8):1026\u20138.","journal-title":"J Drugs Dermatol."},{"issue":"3","key":"5428_CR31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3315\/jdcr.2016.1232","volume":"10","author":"M AbuHilal","year":"2016","unstructured":"AbuHilal M, Walsh S, Shear N. Treatment of recalcitrant erosive oral lichen planus and desquamative gingivitis with oral apremilast. J Dermatol Case Rep. 2016;10(3):56\u20137. https:\/\/doi.org\/10.3315\/jdcr.2016.1232.","journal-title":"J Dermatol Case Rep."},{"issue":"2","key":"5428_CR32","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000447051","volume":"8","author":"J Hafner","year":"2016","unstructured":"Hafner J, Gubler C, Kaufmann K, Nobbe S, Navarini AA, French LE. Apremilast Is effective in lichen planus mucosae-associated stenotic esophagitis. Case Rep Dermatol. 2016;8(2):224\u20136. https:\/\/doi.org\/10.1159\/000447051.","journal-title":"Case Rep Dermatol."},{"issue":"12","key":"5428_CR33","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1111\/jdv.14454","volume":"31","author":"A Nast","year":"2017","unstructured":"Nast A, Spuls PI, van der Kraaij G, Gisondi P, Paul C, Saiag P, et al. European S3-Guideline on the systemic treatment of psoriasis vulgaris - update apremilast and secukinumab - EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2017;31(12):1951\u201363. https:\/\/doi.org\/10.1111\/jdv.14454.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"5428_CR34","unstructured":"Apremilast Investigators Brochure 23.0. Section 6.3. Amgen: 2020."},{"issue":"4","key":"5428_CR35","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1001\/jamadermatol.2014.3513","volume":"151","author":"VL Pascoe","year":"2015","unstructured":"Pascoe VL, Enamandram M, Corey KC, Cheng CE, Javorsky EJ, Sung SM, et al. Using the Physician Global Assessment in a clinical setting to measure and track patient outcomes. JAMA Dermatol. 2015;151(4):375\u201381. https:\/\/doi.org\/10.1001\/jamadermatol.2014.3513.","journal-title":"JAMA Dermatol."},{"issue":"3","key":"5428_CR36","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136. https:\/\/doi.org\/10.1111\/j.1365-2230.1994.tb01167.x.","journal-title":"Clin Exp Dermatol."},{"issue":"1","key":"5428_CR37","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1017\/S0033291700021644","volume":"9","author":"D Goldberg","year":"1979","unstructured":"Goldberg D, Hillier V. A scaled version of the General Health Questionnaire. Psychol Med. 1979;9(1):139\u201345. https:\/\/doi.org\/10.1017\/S0033291700021644.","journal-title":"Psychol Med."},{"issue":"4","key":"5428_CR38","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/00926230290001448","volume":"28","author":"LR Derogatis","year":"2002","unstructured":"Derogatis LR, Rosen R, Leiblum S, Burnett A, Heiman J. The Female Sexual Distress Scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal distress in women. J Sex Marital Ther. 2002;28(4):317\u201330. https:\/\/doi.org\/10.1080\/00926230290001448.","journal-title":"J Sex Marital Ther."},{"key":"5428_CR39","doi-asserted-by":"publisher","first-page":"2e","DOI":"10.1186\/s13063-015-1133-z","volume":"17","author":"RC Simpson","year":"2016","unstructured":"Simpson RC, Murphy R, Bratton DJ, Sydes MR, Wilkes S, Nankervis H, et al. Systemic therapy for vulval erosive lichen planus (the \u2018hELP\u2019 trial): study protocol for a randomised controlled trial. Trials. 2016;17:2e.","journal-title":"Trials"},{"issue":"4","key":"5428_CR40","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/LGT.0000000000000407","volume":"22","author":"RC Simpson","year":"2018","unstructured":"Simpson RC, Murphy R, Bratton DJ, Sydes MR, Wilkes S, Nankervis H, et al. Help for future research: lessons learned in trial design, recruitment, and delivery from the \u2018hELP\u2019 study. J Low Genit Tract Dis. 2018;22(4):405\u20138. https:\/\/doi.org\/10.1097\/LGT.0000000000000407.","journal-title":"J Low Genit Tract Dis"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05428-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-021-05428-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05428-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T09:16:24Z","timestamp":1626772584000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-021-05428-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,20]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5428"],"URL":"https:\/\/doi.org\/10.1186\/s13063-021-05428-w","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,20]]},"assertion":[{"value":"25 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is approved by South-East Regional Committee for Medical and Health Research Ethics in Norway (2018\/1841) and will be performed in accordance with the principles of the Helsinki Declaration. All participants will give their informed consent in writing.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent includes consent to publish the result of the trial. No data from individual persons will be published without additional and specific informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"469"}}